| Name | Title | Contact Details |
|---|
Image Stream Medical is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Littleton, MA. To find more information about Image Stream Medical, please visit www.imagestreammedical.com
Encore Unlimited is a Duluth, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Health Plus PHSP Inc is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
WPS Health Solutions is a nationally regarded government contractor and leader in the insurance industry, serving our communities for more than 70 years. WPS has five divisions committed to delivering high-quality service to our customers. - The WPS Health Insurance division offers affordable health plans for individuals, small businesses, and large businesses, plus benefits administration. - The WPS Government Health Administrators division administers Part A and Part B Medicare benefits—services we have provided since the program`s inception—for millions of seniors in multiple states. - The WPS Military and Veterans Health division serves millions more beneficiaries who are active in the U.S. military, veterans, and their families. - The Arise Health Plan division offers high-value health plans with local service. - The EPIC Specialty Benefits division has offered voluntary non-medical benefits, such as term life, disability, dental, and vision, for more than 25 years. WPS also actively partners with non-profit organizations to help make lasting changes in the communities we serve, with an emphasis on health issues, especially for military and veterans, and women and children.
At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.